CD79-Targeting CAR for B-Cell Malignancy Relapse Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR-T cell therapies targeting CD19 and CD22 are prone to relapse due to antigen escape mechanisms, where B-cell malignancies mutate and become negative for these antigens, leading to treatment resistance.
Innovation Solution
Development of a chimeric antigen receptor (CAR) that specifically binds CD79, a protein component of the B cell receptor, to target B-cell malignancies. The CAR can be designed with various antigen-binding domains such as scFv, Fab, or dAb, and can be combined with other CARs targeting CD19 or CD22 in logic gate configurations to enhance specificity and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR-T cell therapy targets CD19 or CD22 antigens, then initial treatment efficacy is improved, but relapse occurs due to antigen escape mechanisms
Solution Approach 1:
The patent divides the targeting strategy into multiple segments by combining CARs that target different B-cell antigens (CD19, CD22, and/or CD79b). This segmentation allows the therapy to attack the cancer through multiple pathways, preventing the cancer from escaping via a single antigen loss mechanism.
Solution Approach 2:
The patent creates a composite CAR-T cell therapy by integrating multiple CAR constructs with different antigen specificities into a single cell product. This composite approach combines the targeting capabilities of anti-CD19, anti-CD22, and/or anti-CD79b CARs to achieve broader and more durable coverage against B-cell malignancies.
2Device complexity
If a single antigen target is used in CAR design, then the CAR structure is simple, but treatment fails when the antigen is lost through mutation
Solution Approach 1:
The patent segments the CAR-T cell product into multiple functional units, each targeting a different antigen. This can be achieved through multiple independent CAR constructs or a polycistronic design that expresses multiple CARs from a single viral vector, maintaining manageable complexity while improving reliability.
Solution Approach 2:
The patent creates multi-functional CAR-T cells that can recognize and target multiple different B-cell antigens. This universality ensures that the therapy remains effective even if one antigen is lost or mutated, as the CAR-T cells can switch to targeting alternative antigens.
3Reliability
If CD79b is targeted instead of CD19 or CD22, then antigen escape is reduced, but the CAR requires new antigen-binding domain development
Solution Approach 1:
The patent changes the target antigen parameter from conventional choices (CD19, CD22) to CD79b, which has different expression patterns and escape mechanisms. This parameter change requires developing new antigen-binding domains but provides improved resistance to escape mechanisms observed with traditional targets.
Data Source
AI summary
The present invention provides a chimeric antigen receptor (CAR) which specifically binds CD79 as well as a nucleic acid sequence and a vector encoding the CAR. It further provides a cell which expresses the CAR at the cell surface.